MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on June 3, 2008; DOI: 10.1124/mol.108.047969


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.108.047969v1
74/3/697    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, H. H. W.
Right arrow Articles by Kuo, M. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, H. H. W.
Right arrow Articles by Kuo, M. T.


Received for publication April 16, 2008.
Revised June 2, 2008.
Accepted for publication June 2, 2008.

Elevated Glutathione Levels Confers Cellular Sensitization to Cisplatin Toxicity by Upregulation of Copper Transporter hCtr1

Helen H. W. Chen 1, Im-sook Song 1, Anwar Hossain 1, Min-Koo Choi 2, Yoshiaki Yamane 1, Zheng D. Liang 1, Jia Lu 1, Lily Y Wu 1, Zahid Siddik 1, leo W. J. Klomp 3, Naramol Savaraj 4, Macus T. Kuo 5*

1 The University of Texas M. D. Anderson Cancer Center 2 Inje University, Busan, South Korea 3 Univ. Medical Center, Utrecht, Netheerland 4 VA Medical Center, Miamia, FK 5 The University of Tecas M. D. Anderson Cancen Ter

* Address correspondence to: E-mail: tkuo{at}mdanderson.org

Abstract

Previous studies have demonstrated that treating cultured cells with cisplatin (CDDP) upregulated the expression of glutathione (GSH) and its de novo rate-limiting enzyme, glutamate-cysteine ligase (GCL), which consists of catalytic (GCLC) and modifier (GCLM) subunits. It has also been shown that many CDDP-resistant cell lines exhibit high levels of GCLC/GCLM and GSH. Since GSH system is the major intracellular regulator of redox conditions that serve as an important detoxification cytoprotector, these results have been taken into considerations that elevated levels of GCL/GSH are responsible for the CDDP resistance. In contrast to this context, we demonstrated here that overexpression of GSH by transfection with expressing plasmid containing GCLC cDNA conferred sensitization to CDDP through upregulation of human copper transporter 1 (hCtr1), which is also a transporter for CDDP. Depleting GSH levels in these transfected cells reversed CDDP sensitivity with concomitant reduction of hCtr1 expression. While rates of Cu transport were also upregulated in the transfected cells, these cells exhibited biochemical signature of Cu deficiency, suggesting that GSH functions as an intracellular Cu-chelator and that overexpression of GSH can alter Cu metabolism. More importantly, our results reveal a new role of GSH in the regulation of CDDP sensitivity. Overproduction of GSH depletes bioavailable Cu pool, leading to upregulation of hCtr1 and sensitization of CDDP transport and cell killing. These findings also have important implications that modulation of intracellular Cu pool may be a novel strategy for improving chemotherapeutic efficacy of platinum-based antitumor agents.


Key words: Glutathione, Metals and chelators, Toxicant-induced gene express


This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
Z. D. Liang, D. Stockton, N. Savaraj, and M. Tien Kuo
Mechanistic Comparison of Human High-Affinity Copper Transporter 1-Mediated Transport between Copper Ion and Cisplatin
Mol. Pharmacol., October 1, 2009; 76(4): 843 - 853.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics